• Russell P Rosenberg, Richard K Bogan, Jane M Tiller, Ronghua Yang, James M Youakim, Craig Q Earl, and Thomas Roth.
• NeuroTrials Research, Atlanta, GA 30342, USA. russell.rosenberg@atlantasleep.com
• Mayo Clin. Proc. 2010 Jul 1; 85 (7): 630638630-8.

ObjectiveTo assess the effect of armodafinil, the longer-lasting isomer of modafinil, on jet lag disorder.Participants And MethodsThis double-blind, randomized, parallel-group, multicenter study was conducted between September 18, 2008, and February 9, 2009. Adults with a history of jet lag symptoms on previous flights through multiple time zones flew from the United States to France (a 6-hour time zone change) for a 3-day laboratory-based study period. Participants received armodafinil (50 or 150 mg/d) or placebo each morning. Wakefulness was assessed by the coprimary outcomes, mean sleep latency on the Multiple Sleep Latency Test (MSLT) (average of all MSLT sessions across days 1 and 2) and Patient Global Impression of Severity in relation to jet lag symptoms (averaged across days 1 and 2).ResultsA total of 427 participants received armodafinil at 50 mg/d (n=142), armodafinil at 150 mg/d (n=143), or placebo (n=142). Armodafinil at 150 mg/d provided a significant benefit in sleep latency on the MSLT (days 1-2: mean, 11.7 minutes vs 4.8 minutes for placebo; P<.001) and participants' perception of their overall condition in relation to jet lag symptoms (Patient Global Impression of Severity, days 1-2: mean, 1.6 vs 1.9 for placebo; P<.05). The most frequently reported adverse events for armodafinil at 150 mg/d were headache (27%), nausea (13%), diarrhea (5%), circadian rhythm sleep disorder (5%), and palpitations (5%).ConclusionArmodafinil increased wakefulness after eastward travel through 6 time zones.Trial Registrationclinicaltrials.gov identifier: NCT00758498.

28 keywords...

hide…